Dong-A’s novel antibacterial agent receives positive results from Phase 3 clinical trial in severe s

Trius Therapeutics, Inc. on March 25 announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (DA-7218) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including methicillin resistant Staphylococcus aureus (MRSA), Dong-A ST said yesterday.

Dong-A ST (formerly Dong-A Pharmaceutical Co.) entered into a license agreement wit...